Clinical Trial: The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
Study Status: Approved for marketing
Recruit Status: Approved for marketing
Study Type: Expanded Access
Official Title:
Brief Summary: The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.
Detailed Summary:
Sponsor: Alexion Pharmaceuticals
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Alexion Pharmaceuticals
Dates:
Date Received: February 20, 2007
Date Started:
Date Completion:
Last Updated: May 5, 2014
Last Verified: September 2011